Who is the founder of T1D Fund?

Sean Doherty JD is the founder of T1D Fund.

Where is T1D Fund headquartered?

T1D Fund is headquartered in Boston, MA.

What is T1D Fund's total asset value?

T1D Fund has around 0000 in total assets under management.

How many investments has T1D Fund made?

T1D Fund has made 50 investments.

What has T1D Fund invested in?

T1D Fund has made numerous investments in companies like Zag Bio , AltruBio , and vTv Therapeutics within the Drug Delivery, Drug Discovery, and Biotechnology industries.

What has T1D Fund invested in recently?

T1D Fund's latest investment was on 01-Jul-2024 in Zag Bio , a company within the Drug Delivery industry.

T1D Fund Investor Profile: Portfolio & Exits

T1D Fund Overview

Investor Type

Venture Capital

Status

Active

Professionals

18

Investments

50

Portfolio

22

Exits

14

T1D Fund General Information

Company Description

Founded in 2016, T1D Fund is a venture capital firm based in Boston, Massachusetts. The firm seeks to make investments in biotech and pharma companies developing therapeutics, diagnostics, devices, and vaccines for people living with or at risk of developing type 1 diabetes sectors.

Business Details

Website

t1dfund.org

Year Founded

2016

Investor Status

Actively Seeking New Investments

Trade Association

New England Venture Capital Association (NEVCA)

Primary Investor Type

Venture Capital

Corporate Office

50 Milk Street
16th Floor
Boston, MA 02109
United States

+1 (617) 000-0000



T1D Fund Investments (50)

Company Name	Deal Date	Deal Type	Deal Size	Industry	Company Stage	Lead Partner
Zag Bio	01-Jul-2024	Early Stage VC		Drug Delivery	Startup
AltruBio	21-May-2024	00000 00000	00000	Drug Discovery	Clinical Trials - Phase 2
vTv Therapeutics	28-Feb-2024	0000	0000	Biotechnology	Generating Revenue	000000 00000
Orizuru Therapeutics	31-Jan-2024	00000 00000	000.00	Drug Discovery	Pre-Clinical Trials
Cour	30-Jan-2024	00000 00000	00000	Biotechnology	Generating Revenue
SAb Biotherapeutics	14-Nov-2023	0000	000.00	Biotechnology	Generating Revenue/Not Profitable
Seraxis	21-Sep-2023	00000 00000	0000	Biotechnology	Pre-Clinical Trials
Kriya Therapeutics	26-Jul-2023	00000 00000	00000	Drug Discovery	Generating Revenue
Veralox Therapeutics	21-Jun-2023	Later Stage VC	0000	Drug Discovery	Generating Revenue	00000 000000
Diogenx	01-Mar-2023	Early Stage VC	000.00	Drug Discovery	Generating Revenue	00000 000000

You’re viewing 10 of 50 investments. Get the full list »

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

T1D Fund Exits (14)

Company Name	Exit Date	Exit Type	Exit Size
SAb Biotherapeutics	26-Jan-2024	Public Investment 2nd Offering	0000
Bigfoot Biomedical	22-Sep-2023	000000000000
Inversago Pharma	08-Sep-2023	000000000000	00.000
Capillary Biomedical	21-Jul-2022	000000000000	000.00
TetraGenetics	10-Sep-2021	000000000000	0000
Protomer Technologies	14-Jul-2021	000000000000	000
Immunocore Holdings	05-Feb-2021	000	00000
Sana Biotechnology	04-Feb-2021	000	00000
GluSense	01-Feb-2021	Out of Business
ImmusanT	08-Jan-2021	Out of Business

You’re viewing 10 of 14 exits. Get the full list »

T1D Fund Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.